Dose-adjusted EPOCH
Drug . | Dose . | Route . | Treatment days . |
---|---|---|---|
Infused agents* | |||
Etoposide | 50 mg/m2/day | CIV | 1,2,3,4 (96 hours) |
Doxorubicin | 10 mg/m2/day | CIV | 1,2,3,4 (96 hours) |
Vincristine† | 0.4 mg/m2/day | CIV | 1,2,3,4 (96 hours) |
Bolus agents | |||
Cyclophosphamide (cycle 1) | |||
CD4+ cells ≥ 100/mm3 | 375 mg/m2/day | IV | 5 |
CD4+ cells < 100/mm3 | 187 mg/m2/day | IV | 5 |
Cyclophosphamide dose-adjustment (after cycle 1)‡ | |||
nadir ANC > 500/μL | ↑ 187 mg above previous cycle | — | — |
nadir ANC < 500/μL or platelets < 25 000/μL | ↓ 187 mg below previous cycle | — | — |
Prednisone | 60 mg/m2/day | PO | 1,2,3,4,5 |
Filgrastim | 5 μg/kg/day | SC | 6 → ANC > 5000/μL (past nadir) |
Next cycle§ | Day 21 |
Drug . | Dose . | Route . | Treatment days . |
---|---|---|---|
Infused agents* | |||
Etoposide | 50 mg/m2/day | CIV | 1,2,3,4 (96 hours) |
Doxorubicin | 10 mg/m2/day | CIV | 1,2,3,4 (96 hours) |
Vincristine† | 0.4 mg/m2/day | CIV | 1,2,3,4 (96 hours) |
Bolus agents | |||
Cyclophosphamide (cycle 1) | |||
CD4+ cells ≥ 100/mm3 | 375 mg/m2/day | IV | 5 |
CD4+ cells < 100/mm3 | 187 mg/m2/day | IV | 5 |
Cyclophosphamide dose-adjustment (after cycle 1)‡ | |||
nadir ANC > 500/μL | ↑ 187 mg above previous cycle | — | — |
nadir ANC < 500/μL or platelets < 25 000/μL | ↓ 187 mg below previous cycle | — | — |
Prednisone | 60 mg/m2/day | PO | 1,2,3,4,5 |
Filgrastim | 5 μg/kg/day | SC | 6 → ANC > 5000/μL (past nadir) |
Next cycle§ | Day 21 |
Data are for cycle 1, except where noted in “Cyclophosphamide dose-adjustment.” — represents not applicable.
Etoposide, doxorubicin, and vincristine can be admixed in the same solution. Etoposide, doxorubicin, and vincristine are never dose-adjusted for hematologic toxicity.
Vincristine dose should never be routinely capped.
Dose based on previous cycle absolute neutrophil count (ANC) nadir (CBC BIW); maximum cyclophosphamide dose 750 mg/m2.
Begin day 21 if ANC ≥ 1000/μL and platelets ≥ 50 000/μL.